Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains

Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains

Thumbnail Image
Download
Name

nihms-1823414.pdf

Description
Accepted version
Size

2.99 MB

Format

Adobe PDF

Checksum (MD5)

355d2711538ff8bda2236189bbfb2b71

sword-2023-01-10T17:56:30.original.xml (130 B)
Original SWORD entry document
Author(s)
Gordon, Khloe S
•
Kyung, Taeyoon
•
Perez, Caleb R
•
Holec, Patrick V
•
Ramos, Azucena
•
Zhang, Angela Q
•
Agarwal, Yash
•
Liu, Yunpeng
•
Koch, Catherine E
•
Starchenko, Alina
more
Date Issued
2022
Journal
Nature Biomedical Engineering
Publisher
Springer Science and Business Media LLC
Citation
Gordon, Khloe S, Kyung, Taeyoon, Perez, Caleb R, Holec, Patrick V, Ramos, Azucena et al. 2022. "Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains." Nature Biomedical Engineering, 6 (7).
Version
Author's final manuscript
Abstract
The immunostimulatory intracellular domains (ICDs) of chimaeric antigen receptors (CARs) are essential for converting antigen recognition into antitumoural function. Although there are many possible combinations of ICDs, almost all current CARs rely on combinations of CD3𝛇, CD28 and 4-1BB. Here we show that a barcoded library of 700,000 unique CD19-specific CARs with diverse ICDs cloned into lentiviral vectors and transduced into Jurkat T cells can be screened at high throughput via cell sorting and next-generation sequencing to optimize CAR signalling for antitumoural functions. By using this screening approach, we identified CARs with new ICD combinations that, compared with clinically available CARs, endowed human primary T cells with comparable tumour control in mice and with improved proliferation, persistence, exhaustion and cytotoxicity after tumour rechallenge in vitro. The screening strategy can be adapted to other disease models, cell types and selection conditions, and could be used to improve adoptive cell therapies and to expand their utility to new disease indications.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Biology
Harvard University--MIT Division of Health Sciences and Technology
Ragon Institute of MGH, MIT and Harvard
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/147045
DOI of Published Version
https://doi.org/10.1038/S41551-022-00896-0
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.